IL17A and systemic lupus erythematosus: For instance, the inhibition of IL-6 receptor and Janus kinase (JAK) is effective in treating patients with anemia and rheumatoid arthritis [89]; antibodies against IL-17 or IL-17 receptor have been used for psoriasis treatment [84]; CD19 CAR-T cell therapy, in addition to its application in B-cell lymphoma, has recently been used for patients with refractory systemic lupus erythematosus (SLE) [85]; low-dose IL-2 therapy also resulted in improvement in patients with SLE or psoriatic arthritis [60].